Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
An update from Aspire Biopharma Holdings ( (ASBP) ) is now available.
On January 1, 2026, Aspire Biopharma Holdings entered into exchange agreements with certain former PowerUp Acquisition Corp. sponsor-lenders to convert approximately $1.75 million of outstanding debt, originally incurred under March 4 and May 9, 2024 subscription agreements, into common stock. Under the deals, each holder may submit up to four exchange notices by January 31, 2026, swapping tranches of up to 30% of their respective balances at a per-share price equal to the prior trading day’s closing price minus $0.01, with the resulting shares issued as freely tradeable stock; the company also gained flexibility to repay portions of remaining balances from the proceeds of any future financing above $3 million, potentially improving its capital structure by reducing debt while giving accredited investors structured equity and cash-out options.
More about Aspire Biopharma Holdings
Aspire Biopharma Holdings operates in the biopharmaceutical sector and is the corporate successor to PowerUp Acquisition Corp., a special purpose acquisition company whose sponsors previously provided financing to the business through subscription agreements in 2024.
Average Trading Volume: 29,352,602
Technical Sentiment Signal: Sell
Current Market Cap: $16.64M
For detailed information about ASBP stock, go to TipRanks’ Stock Analysis page.